Live Breaking News & Updates on Daratumumab|Page 1

Stay updated with breaking news from Daratumumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment. ....

Operationalizing Treatment , Multiple Myeloma , Treatment Setting , Combination Therapy , Cytokine Release Syndrome ,

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings. ....

United States , Vaishali Sanchorawala , Heather Landau , Jeffrey Zonder , Peer Exchange , American Society Of Hematology , American Society , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis. ....

Vaishali Sanchorawala , Jeffrey Zonder , Heather Landau , Peer Exchange , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,

Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM

The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
....

Dara Imi , Blood Cancer , Multiple Myeloma , Relapsed Refractory Multiple Myeloma ,

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis. ....

United States , Vaishali Sanchorawala , Heather Landau , Jeffrey Zonder , Peer Exchange , American Society Of Hematology , American Society , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,